Abstract

Tumour detection with high selectivity and sensitivity is crucial for delineating tumour margins and identifying metastatic foci during image-guided surgery. Optical nanoprobes with preferential tumour accumulation is often limited by inefficient amplification of biological signals. Here, we report the design of a library of hydrophobic core-tunable ultra-pH-sensitive nanoprobes (HUNPs) for orthogonally amplifying tumour microenvironmental signals on multiple tumour models. We find that tuning the hydrophobicity of nanoparticle core composition with non-ionizable monomers can enhance cellular association of HUNPs by more than ten-fold, resulting in a high cellular internalization efficiency of HUNPs with up to 50% in tumours. Combining high tumour accumulation and high cell internalization efficiency, HUNPs show orthogonally amplified fluorescence signals, permitting the precise locating and delineating margins between malignant lesions and normal tissues with high contrast-to-noise ratio and resolution. Our study provides key strategies to design nanomedicines with high intracellular bioavailability for cancer detection, drug/gene delivery, and therapy.

Optical nanoprobes with preferential tumour accumulation is often limited by inefficient amplification of biological signals. Here, the authors report a hydrophobic core-tunable nanoprobe orthogonally amplifying tumour microenvironmental signals and demonstrating clear delineation between malignant lesions and normal tissues on multiple tumour models.

Details

Title
Tuning nanoparticle core composition drives orthogonal fluorescence amplification for enhanced tumour imaging
Author
Pan, Meijie 1 ; Zhao, Ruiyang 2 ; Fu, Chuanxun 2 ; Tang, Mingmei 2 ; Zhou, Jiayi 2 ; Ma, Bin 2 ; Liu, Jianxiong 2 ; Yang, Ye 2 ; Chen, Binlong 2   VIAFID ORCID Logo  ; Zhang, Qiang 1 ; Wang, Yiguang 3   VIAFID ORCID Logo 

 Peking University, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319); Peking University, Beijing Key Laboratory of Molecular Pharmaceutics, School of Pharmaceutical Sciences, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319) 
 Peking University, Beijing Key Laboratory of Molecular Pharmaceutics, School of Pharmaceutical Sciences, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319) 
 Peking University, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319); Peking University, Beijing Key Laboratory of Molecular Pharmaceutics, School of Pharmaceutical Sciences, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319); Peking University, Chemical Biology Center, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319) 
Pages
7824
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3101377451
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.